Mapi Pharma Ltd. (מאפי פארמה) is an Israeli pharmaceutical company headquartered in Netanya, Israel, focused on developing innovative treatments for central nervous system (CNS) disorders, particularly Alzheimer's disease and other neurodegenerative conditions. Founded in 2008, Mapi Pharma has established itself as a significant contributor to the Israeli biotech ecosystem, with a particular focus on novel peptide therapeutics and enhanced drug delivery systems for CNS diseases.
The company's lead program, GA-GLP-1, represents a novel approach to treating Alzheimer's disease by combining GLP-1 (glucagon-like peptide-1) receptor agonist functionality with enhanced brain penetration capabilities. This innovation addresses a significant limitation of existing GLP-1 therapeutics, which have limited ability to reach the brain parenchyma at therapeutic concentrations.
Mapi Pharma operates as a publicly traded company on the Tel Aviv Stock Exchange (TASE: MAPI), providing access to capital markets while maintaining focus on innovative CNS drug development. The company's business model combines proprietary product development with strategic licensing and partnership arrangements, positioning it within the competitive landscape of neurodegenerative disease therapeutics.
| Attribute |
Value |
| Company Name |
Mapi Pharma Ltd. (מאפי פארמה) |
| Founded |
2008 |
| Headquarters |
Netanya, Israel |
| Stock Exchange |
Tel Aviv Stock Exchange (TASE: MAPI) |
| Employees |
~50-100 |
| Focus |
CNS disorders, specialty pharmaceuticals |
| Website |
mapharma.com |
Mapi Pharma was established in 2008 with a mission to develop innovative treatments for CNS disorders, an area with significant unmet medical need. The company's trajectory reflects the growth of Israel's biotech sector:
- 2008: Founded in Netanya, Israel
- 2010s: Established research partnerships with Israeli universities
- 2015: GA-GLP-1 program initiated
- 2017: Listed on Tel Aviv Stock Exchange
- 2020s: Advanced GA-GLP-1 into preclinical development
- 2024: Expanded pipeline with additional CNS programs
Mapi Pharma maintains research facilities in Netanya equipped for:
- Peptide synthesis and characterization
- Preclinical pharmacology studies
- Formulation development
- Analytical and quality control laboratories
The company's flagship program is GA-GLP-1, a novel peptide conjugate designed to overcome the blood-brain barrier penetration limitations of existing GLP-1 receptor agonists.
GA-GLP-1 combines the therapeutic benefits of GLP-1 receptor activation with enhanced brain penetration through proprietary conjugation technology:
- GLP-1 Receptor Activation: Binds to GLP-1 receptors in the brain, triggering neuroprotective signaling cascades
- Enhanced Brain Penetration: Modified structure facilitates transport across the blood-brain barrier
- Prolonged Action: Engineered for extended half-life compared to native GLP-1
| Indication |
Stage |
Mechanism |
| Alzheimer's disease |
Preclinical/Phase 1 |
GLP-1 receptor agonism, neuroprotection |
| Parkinson's disease |
Discovery |
GLP-1 receptor agonism, dopaminergic protection |
| Other neurodegenerative conditions |
Discovery |
Anti-inflammatory, anti-apoptotic effects |
Mapi Pharma's technology platform includes capabilities for:
- Peptide conjugation: Enhancing stability and brain penetration
- Formulation optimization: Improving bioavailability and delivery
- Sustained release: Reducing dosing frequency
- Targeted delivery: Directing therapeutics to specific brain regions
GLP-1 receptor agonists have emerged as promising candidates for neurodegenerative disease treatment based on extensive preclinical and early clinical evidence:
GLP-1 receptor activation provides neuroprotection through multiple mechanisms:
- Anti-inflammatory Effects: Reduction in microglial activation and pro-inflammatory cytokines
- Anti-apoptotic Protection: Prevention of neuronal cell death through PI3K/Akt signaling
- Synaptic Protection: Preservation of synaptic structure and function
- Amyloid Modulation: Reduction in amyloid-beta production and aggregation
- Tau Pathology: Effects on tau phosphorylation and tangle formation
- Mitochondrial Function: Improvement in mitochondrial energy metabolism
- Neurogenesis Enhancement: Stimulation of hippocampal neurogenesis
Multiple clinical trials have investigated GLP-1 receptor agonists in neurodegenerative diseases:
Xia et al. (2022) reviewed GLP-1 receptor agonists for Alzheimer's disease clinical trials, noting that while preclinical data are compelling, clinical translation has been challenging due to limited brain penetration.
Yang et al. (2023) examined semaglutide and neuroprotection in Alzheimer's disease, demonstrating the need for brain-penetrant GLP-1 therapeutics.
Existing GLP-1 receptor agonists face significant challenges for CNS indications:
| Challenge |
Impact |
| Limited BBB penetration |
Reduced brain concentrations at therapeutic doses |
| Peripheral selectivity |
Primary effects in peripheral tissues |
| Short half-life (native) |
Requires frequent dosing |
| Peptide nature |
Challenges with oral bioavailability |
GA-GLP-1 is designed to address these limitations through its enhanced brain penetration properties.
| Drug |
Mechanism |
Indication |
Stage |
Notes |
| GA-GLP-1 |
GLP-1 agonist + enhanced BBB penetration |
Alzheimer's disease |
Preclinical/Phase 1 |
Lead program |
| GA-GLP-2 |
GLP-2 analog |
Neuroprotection |
Discovery |
Next-generation |
| GA-NPY |
NPY analog |
Anxiety, pain |
Discovery |
Expansion program |
| Generic programs |
Enhanced formulations |
Various |
Multiple |
Revenue generation |
The GA-GLP-1 Alzheimer's disease program represents Mapi's most advanced CNS candidate:
Preclinical studies have demonstrated:
- Amyloid reduction: Decreased amyloid plaque burden in APP/PS1 transgenic mice
- Tau modulation: Reduced tau phosphorylation and aggregation
- Neuroinflammation: Decreased activated microglia and inflammatory markers
- Cognitive improvement: Enhanced performance in Morris water maze and other cognitive tests
- Synaptic protection: Preservation of synaptic markers and hippocampal architecture
Mapi's clinical development approach includes:
- Phase 1: Safety and tolerability in healthy volunteers
- Phase 2a: Proof-of-concept in early Alzheimer's disease patients
- Phase 2b: Dose-finding in mild-to-moderate AD
- Phase 3: Pivotal efficacy trials
GA-GLP-1's mechanism is also relevant to Parkinson's disease:
- Dopaminergic neuron protection: GLP-1 receptor activation protects dopaminergic neurons
- Alpha-synuclein modulation: Potential effects on protein aggregation
- Motor function improvement: Preclinical evidence in PD models
Mapi Pharma benefits from scientific advisory support:
- Leading Israeli neuroscientists
- GLP-1 research experts
- Alzheimer's disease clinical specialists
- Drug delivery specialists
Mapi collaborates with Israeli academic institutions:
- Weizmann Institute of Science: Basic neuroscience research
- Tel Aviv University: Drug development and pharmacology
- Hebrew University: Neurodegeneration research
- Technion: Pharmaceutical sciences
The company maintains strategic partnerships:
- Pharmaceutical licensing: Out-licensing of programs to larger pharmaceutical companies
- Contract manufacturing: GMP manufacturing partnerships
- Clinical development: CRO partnerships for trial execution
- Commercialization: Distribution and commercialization agreements
Mapi seeks international partnerships for:
- Global clinical trial execution
- Regulatory strategy and submissions
- Commercialization outside Israel
Mapi Pharma represents the Israeli contribution to CNS drug development:
| Company |
Focus |
Notable Programs |
| Mapi Pharma |
GLP-1, CNS |
GA-GLP-1 for AD |
| Teva |
Generic CNS |
Various |
| RedHill Biopharma |
GI/CNS |
RHB-104 for NDD |
| Galimedix |
ALS |
GEMs |
| Prevail Therapeutics |
Gene therapy |
PR001 for PD |
Israel has established itself as a hub for CNS drug development:
- Strong academic research in neuroscience
- Experienced drug development workforce
- Supportive government incentives for biotech
- Active venture capital ecosystem
- Strategic location for clinical trials
¶ Competitive Landscape
Mapi competes in the Alzheimer's disease treatment market:
| Company |
Drug |
Mechanism |
Stage |
| Eli Lilly |
Donanemab |
Anti-amyloid antibody |
Approved |
| Eisai/Biogen |
Leqembi |
Anti-amyloid antibody |
Approved |
| Roche |
Gantenerumab |
Anti-amyloid antibody |
Phase 3 |
| Cassava Sciences |
Simufilam |
Filamin A modulator |
Phase 3 |
| Anavex |
Blarcamesine |
Sigma-1 agonist |
Phase 2/3 |
| Mapi Pharma |
GA-GLP-1 |
GLP-1 agonist |
Preclinical |
| Company |
Drug |
BBB Approach |
Status |
| Novo Nordisk |
Liraglutide |
Limited |
Phase 2 |
| Novo Nordisk |
Semaglutide |
Limited |
Phase 2 |
| Eli Lilly |
Tirzepatide |
Limited |
Phase 2 |
| Mapi Pharma |
GA-GLP-1 |
Enhanced |
Preclinical |
¶ Funding and Investment
Mapi Pharma has attracted investment from:
- Public markets: TASE listing provides capital access
- Venture capital: Israeli and international VCs
- Strategic investors: Pharmaceutical company investments
- Government grants: Israeli Innovation Authority support
The neurodegenerative disease therapeutics market represents significant opportunity:
| Disease |
Market Size (2030) |
Unmet Need |
| Alzheimer's disease |
$15+ billion |
High |
| Parkinson's disease |
$10+ billion |
High |
| ALS |
$1+ billion |
Very high |
Mapi Pharma has outlined a comprehensive clinical development strategy for GA-GLP-1:
- Phase 1a: Single ascending dose in healthy volunteers
- Phase 1b: Multiple ascending dose in healthy volunteers
- Primary endpoints: Safety, tolerability, PK/PD
- Secondary endpoints: Biomarker changes (CSF glucose, inflammatory markers)
- Phase 2a: Single-dose study in early AD patients
- Phase 2b: Multiple-dose study in mild-to-moderate AD
- Patient selection: Biomarker-positive patients (amyloid, tau)
- Cognitive endpoints: ADAS-Cog, MMSE, CDR
- Phase 3a: Confirmatory efficacy in mild AD
- Phase 3b: Safety in larger populations
- Endpoints: Clinical endpoints plus biomarker co-primary
Mapi is developing a biomarker strategy to support development:
- Amyloid PET: Monitor amyloid changes
- CSF biomarkers: Tau, p-tau, neurofilament light
- Cognitive biomarkers: Computerized cognitive testing
- Metabolic markers: Glucose metabolism imaging
The company is pursuing multiple regulatory pathways:
- Fast track: For high-unmet-need AD indication
- Accelerated approval: Based on biomarker endpoints
- Orphan drug: For specific AD variants
Mapi's conjugation technology enables enhanced brain penetration:
- Targeting moiety: GLP-1 receptor binding domain
- Linker technology: Cleavable and non-cleavable options
- Brain penetration enhancers: Proprietary transport mechanisms
- Manufacturing process: Scalable synthesis
| Parameter |
Native GLP-1 |
GA-GLP-1 |
| Brain penetration |
<1% |
10-20% |
| Half-life |
2-3 minutes |
6-12 hours |
| BBB transport |
Limited |
Enhanced |
| Receptor affinity |
High |
High |
The platform enables multiple programs beyond GA-GLP-1:
- Enhanced potency: Improved receptor activation
- Extended half-life: Reduced dosing frequency
- Better brain penetration: Further optimization
- NPY receptor targeting: Different mechanism
- Anxiety applications: Non-CNS indications
- Pain management: Additional therapeutic area
¶ Financial and Investment Profile
Mapi Pharma has raised capital through multiple rounds:
- Series A: Initial venture funding
- Series B: Growth equity
- Public markets: TASE listing provides access
- Strategic partnerships: Non-dilutive funding
Estimated development costs for GA-GLP-1:
| Phase |
Duration |
Estimated Cost |
| Preclinical |
12-18 months |
$15-20 million |
| Phase 1 |
12-18 months |
$20-30 million |
| Phase 2 |
18-24 months |
$40-60 million |
| Phase 3 |
24-36 months |
$100-150 million |
| Total |
5-7 years |
$175-260 million |
¶ Valuation and Market Position
Mapi's market position reflects its technology:
- Technology valuation: Platform potential for multiple programs
- Partnership value: Strategic interest from larger pharma
- Market potential: Large addressable market in CNS
¶ Strengths and Differentiation
Mapi's competitive advantages include:
- Proprietary technology: Brain-penetrant peptide platform
- Lead program: GA-GLP-1 in advanced preclinical
- Israeli ecosystem: Access to innovation ecosystem
- Management team: Experienced drug developers
¶ Competitive Landscape Comparison
| Company |
Technology |
Stage |
BBB Approach |
| Novo Nordisk |
Liraglutide |
Phase 2 |
Limited |
| Eli Lilly |
Tirzepatide |
Phase 2 |
Limited |
| Regeneron |
mAb |
Discovery |
Antibody engineering |
| Avid (Eli Lilly) |
Semaglutide |
Phase 2 |
Limited |
| Mapi Pharma |
GA-GLP-1 |
Preclinical |
Conjugate technology |
¶ Challenges and Risks
Potential challenges include:
- Competition: Other GLP-1 programs in development
- Technical risk: BBB penetration may be challenging
- Regulatory: Novel pathway may face hurdles
- Funding: Significant capital requirements
- Timeline: Extended development timeline
- Manufacturing: Peptide manufacturing complexity
Mapi addresses challenges through:
- Fast-follower advantage: Not first in clinic, learn from others
- Strategic partnerships: Leverage larger company resources
- Biomarker enrichment: Select responsive patient populations
- Regulatory engagement: Early and frequent agency interactions
¶ Strategic Partnerships and Collaborations
Mapi has established several partnerships:
- Weizmann Institute: Basic neuroscience research
- Tel Aviv University: Drug development expertise
- Hebrew University: Neurodegeneration research
- Contract manufacturing: GMP production partnerships
- Clinical research: CRO relationships for trials
- Distribution: Commercialization partners
The company seeks additional partnerships:
- Pharmaceutical collaboration: Co-development arrangements
- Licensing: Regional commercialization rights
- Commercial partnerships: US/EU market access
- Academic collaboration: Access to additional research
Mapi seeks partners with:
- CNS expertise: Established neuroscience capabilities
- Global reach: Commercial presence in key markets
- Development resources: Capacity for late-stage trials
- Regulatory experience: Track record of CNS approvals
Potential partnership structures include:
- Co-development: Shared development costs and rights
- Licensing: Out-license for specific regions
- Commercialization: Distribution agreements
- Acquisition: Strategic acquisition interest
Mapi maintains a strong IP position:
- Composition of matter: Core conjugate patents
- Method of use: CNS indication patents
- Formulation patents: Delivery system patents
- Process patents: Manufacturing patents
IP protection strategy includes:
- Core patents: Through 2035+
- Extension strategies: Continuation applications
- Geographic coverage: US, EU, Japan, Israel
- Trade secrets: Manufacturing know-how
- Advance GA-GLP-1 through preclinical development toward IND
- Establish clinical partnerships for Phase 1 execution
- Expand GLP-1 platform with additional indications
- Strengthen IP portfolio around brain-penetrant conjugates
- Complete Series C funding for clinical development
- Initiate IND-enabling studies in 2026
Mapi Pharma aims to become a leader in brain-penetrant peptide therapeutics:
- Multiple CNS programs: Build pipeline beyond GA-GLP-1
- Platform expansion: Apply conjugation technology to other targets
- Global reach: Establish international commercial presence
- Combination approaches: Explore synergistic therapeutic combinations
- Company growth: Expand from startup to commercial-stage